Patent 8664239
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-flash
No PTAB proceedings on file. This patent has not been challenged through Inter Partes Review, Post-Grant Review, or Covered Business Method review at the USPTO. The absence is itself a signal — well-asserted patents eventually attract IPRs.
Cases on file (2)
Group view →Specific litigation cases in our database that name US patent 8664239. The free-form analysis below may also discuss cases beyond this list.
- Veloxis Pharmaceuticals AS v. Zydus Cadila et al.filed Apr 23, 20261:26-cv-00467Delaware District CourtOpen
Defendants: Zydus Cadila and Zydus Lifesciences Ltd
Other patents asserted: 11419823, 10864199, 8685998, 11123331, 12403095, 10166190, 11110081, 12083103, 9549918
The accused products are the 0.75 mg, 1 mg, and 4 mg extended-release tacrolimus tablets sold under the brand name ENVARSUS XR.
- Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. et al.filed Jul 7, 2022District of Delawareongoing
Defendants: Accord Healthcare, Inc. and Intas Pharmaceuticals LTD.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Litigation involving US Patent 8,664,239 includes the following case:
1. Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. and [Intas Pharmaceuticals LTD.](/litigations/by-defendant/Intas%20Pharmaceuticals%20LTD.)
- Plaintiff(s): Veloxis Pharmaceuticals, Inc.
- Defendant(s): Accord Healthcare, Inc. and Intas Pharmaceuticals LTD.
- Jurisdiction: District of Delaware
- Case Number: Not explicitly provided, but the article mentions it was filed in the District of Delaware. Further search would be needed to pinpoint the exact case number for this specific patent within the multi-patent lawsuit.
- Filing Date: July 7, 2022
- Outcome or Current Status: This case was filed in response to Accord Healthcare's submission of an Abbreviated New Drug Application (ANDA) to the FDA, seeking approval to market generic versions of Veloxis's ENVARSUS XR (tacrolimus extended-release tablets) prior to the expiration of several patents, including US 8,664,239. Veloxis alleges patent infringement, seeking to prevent the defendants from manufacturing their ANDA products and requesting damages if the products are launched. The case was ongoing as of the July 8, 2022, article.
Google Patents also indicates a US case filed in Delaware District Court with case number 1:26-cv-00467 that includes US8664239. While the plaintiff and defendant are not specified in the Google Patents listing, this indicates ongoing litigation related to the patent.
Generated 5/31/2026, 6:49:18 PM